# Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

> **NCT01275248** · PHASE2 · TERMINATED · sponsor: **Transcept Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Obsessive-compulsive Disorder

## Interventions

- **DRUG:** Ondansetron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01275248
- **Lead sponsor:** Transcept Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275248, "Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01275248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*